# A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

> **NCT01097070** · PHASE2 · COMPLETED · sponsor: **Myrexis Inc.** · enrollment: 35 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Bevirimat

## Key facts

- **NCT ID:** NCT01097070
- **Lead sponsor:** Myrexis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2010-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097070, "A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01097070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*